DEFINE-PCI Study: 60 Second Insights
Published: 20 March 2019
-
Views:
10 -
Likes:
7
-
Views:
10 -
Likes:
7
-
Up Next
-
Part 3 | Session 3 Takashi Akasaka
-
Part 3 | Session 4 Bruce Samuels
-
Part 4 | Session 1 Justin Davies
-
Part 4 | Session 2 Allen Jeremias
-
Part 4 | Session 3 Takashi Akasaka
-
Part 4 | Session 4 Bruce Samuels
-
Part 5 | Session 1 Justin Davies
-
Part 5 | Session 2 Allen Jeremias
-
Part 6 | Session 1 Justin Davies
-
Part 6 | Session 2 Allen Jeremias
-
Part 7 | Session 1 Justin Davies
-
Part 7 | Session 2 Allen Jeremias
-
Part 8 | Session 1 Justin Davies
-
Part 8 | Session 2 Allen Jeremias
-
Part 8 | Session 3 Takashi Akasaka
-
Part 8 | Session 4 Bruce Samuels
-
Part 9 | Session 1 Justin Davies
-
Part 9 | Session 2 Allen Jeremias
-
Part 9 | Session 3 Takashi Akasaka
-
Part 9 | Session 4 Bruce Samuels
-
Part 10 | Session 1 Justin Davies
-
Part 10 | Session 2 Allen Jeremias
-
Part 10 | Session 3 Takashi Akasaka
-
Part 10 | Session 4 Bruce Samuels
-
Part 11 | Session 1 Justin Davies
-
Part 11 | Session 2 Allen Jeremias
-
Part 11 | Session 3 Takashi Akasaka
-
Part 11 | Session 4 Bruce Samuels
-
Part 12 | Session 1 Justin Davies
-
Part 12 | Session 2 Allen Jeremias
-
Part 12 | Session 3 Takashi Akasaka
-
Part 12 | Session 4 Bruce Samuels
-
Part 1 | Session 1 Justin Davies Justin E Davies
-
Part 1 | Session 2 Allen Jeremias Allen Jeremias
-
Part 1 | Session 3 Takashi Akasaka Takashi Akasaka
-
Part 1 | Session 4 Bruce Samuels Bruce Samuels
-
Part 2 | Session 1 Justin Davies Justin E Davies
-
Part 2 | Session 2 Allen Jeremias Allen Jeremias
-
Part 2 | Session 3 Takashi Akasaka Takashi Akasaka
-
Part 2 | Session 4 Bruce Samuels Bruce Samuels
-
Part 3 | Session 1 Justin Davies Justin E Davies
Overview
A series of 60-second interviews where Justin Davies, Allen Jeremias, Takashi Akasaka and Bruce Samuels provide their thoughts on the DEFINE-FLAIR Study.
More from this programme
Part 1
How has Define-FLAIR affected your clinical practice?
Part 2
In what kind of scenarios would residual ischaemia be addressable or not?
Part 3
How does residual ischaemia impact the healthcare system?
Part 4
What has been your experience with tools like iFR co-registration?
Part 5
What's next in the research pipeline?
2 sessions | |
Justin Davies | Watch now |
Allen Jeremias | Watch now |
Part 6
How will it change your clinical practice?
2 sessions | |
Justin Davies | Watch now |
Allen Jeremias | Watch now |
Part 7
What were the key findings from DEFINE-PCI?
2 sessions | |
Justin Davies | Watch now |
Allen Jeremias | Watch now |
Part 8
Do you think the broader interventional community believes post-PCI ischaemia is a real problem?
Part 9
How is DEFINE PCI different from earlier post-PCI ischaemia studies?
Part 10
Why was DEFINE PCI done, is there precedent for post-PCI ischaemia?
Part 11
What would be surprising to see from DEFINE PCI?
Part 12
What do we hope DEFINE PCI will shed light on?
Faculty Biographies
Allen Jeremias
Director of Interventional Cardiology Research and Associate Director, Cardiac Catheterization
Dr Allen Jeremias, MD, MSc is an interventional cardiologist at St. Francis Hospital, Roslyn, NY and Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory. He is also the Director of the Physiology Core Laboratory at the Cardiovascular Research Foundation, New York, NY.
Dr Jeremias earned his medical degree at Heinrich-Heine-University School of Medicine in Düsseldorf, Germany, and a Master of Science degree at Harvard Medical School. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, as well as Beth Israel Deaconess Medical Center, Harvard Medical School.